Findings

What do systematic reviews say?

754 questions · 769 findings · 35 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 228 · 29.6%GRADE not reported 3 · 0.4%Very low 215 · 28%Low 245 · 31.9%Moderate 74 · 9.6%High 4 · 0.5%

Heparin vs placebo

Non‐graft thrombosis · kidney transplant recipients

1 finding from 1 review

Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Eculizumab vs placebo or alternative treatment

Death · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Remission · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Change in eGFR · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Health‐related quality of life · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
44 participants
Very low

Ravulizumab vs placebo or alternative treatment

Adverse events · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Meningococcal infection · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Eculizumab vs placebo or alternative treatment

Remission · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Change in eGFR · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
88 participants
Very low

Eculizumab vs placebo or alternative treatment

Health‐related quality of life · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Adverse events · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Meningococcal infection · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Death · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Antibiotics vs no treatment

Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether antibiotics changes incidence of HUS compared with no treatment (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.57 [0.11, 2.81]
1 study · 47 participants
Very low

Bovine colostrum vs placebo

Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether synsorb Pk changes incidence of HUS compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.93 [0.39, 2.22]
1 study · 353 participants
Very low

Synsorb Pk vs placebo

Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Urtoxazumab (3.0 mg/kg) vs placebo

Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether urtoxazumab (3.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.14]
1 study · 71 participants
Very low